Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

Dig Liver DisAug 30, 2026 (epub)
Clinical ResearchOncology (Medical)

Judith Raimbourg, Damien Botsen, Simon Pernot et al.

✦ AI-curated · Sources linked

In 30 seconds

The GRACIE trial is a multicenter, open-label phase II study evaluating the efficacy and safety of Ivonescimab combined with FOLFOX chemotherapy in 88 patients with advanced or metastatic gastric cancer or esophagogastric junction cancer. The study aims to assess the Objective Response Rate (ORR) in treatment-naïve patients and those with prior treatment. Preliminary results will inform future phase III trials.

Key findings

  • The primary objective is to evaluate the Objective Response Rate (ORR) after central review according to RECIST v1.1.
  • Patients included have an ECOG performance status of 0-1.
  • The study involves 88 patients across 18 French centers.

Why it matters

Understanding the efficacy of Ivonescimab in combination with chemotherapy could provide new treatment options for patients with advanced gastric and esophagogastric junction cancers, particularly in those with limited therapeutic alternatives.

Source

PubMed · PMID 42669571

Published in Dig Liver Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.